ES478199A1 - Un procedimiento para la preparacion de etalazinas. - Google Patents

Un procedimiento para la preparacion de etalazinas.

Info

Publication number
ES478199A1
ES478199A1 ES478199A ES478199A ES478199A1 ES 478199 A1 ES478199 A1 ES 478199A1 ES 478199 A ES478199 A ES 478199A ES 478199 A ES478199 A ES 478199A ES 478199 A1 ES478199 A1 ES 478199A1
Authority
ES
Spain
Prior art keywords
cardiac
compounds
heart failure
piperidinophthalazines
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES478199A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp SRL
Original Assignee
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp SRL filed Critical Pfizer Corp SRL
Publication of ES478199A1 publication Critical patent/ES478199A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Esta invención se refiere a agentes terapéuticos, que son nuevos derivados de la ftalazina, y especialmente se refiere a estos derivados con un grupo piperidino sustituido en la posición 1. Los compuestos de la invención son inhibidores de la fosfodiesterasa y estimulantes cardíacos, de los que una clase preferida aumenta selectivamente la fuerza de la contracción mio cardial sin producir aumentos significativos del ritmo cardiaco. Los compuestos son útiles en el tratamiento curativo o profiláctico de las condiciones cardíacas , como fallo cardiaco congestivo, angina de pecho arritmias cardiacas y fallo cardíaco agudo.
ES478199A 1977-06-03 1979-03-01 Un procedimiento para la preparacion de etalazinas. Expired ES478199A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2358277 1977-06-03

Publications (1)

Publication Number Publication Date
ES478199A1 true ES478199A1 (es) 1980-01-16

Family

ID=10198020

Family Applications (4)

Application Number Title Priority Date Filing Date
ES470470A Expired ES470470A1 (es) 1977-06-03 1978-06-02 Un procedimiento para la preparacion de ftalazinas
ES478201A Expired ES478201A1 (es) 1977-06-03 1979-03-01 Un procedimiento para la preparacion de ftalazinas.
ES478200A Expired ES478200A1 (es) 1977-06-03 1979-03-01 Un procedimiento para la preparacion de ftalazinas.
ES478199A Expired ES478199A1 (es) 1977-06-03 1979-03-01 Un procedimiento para la preparacion de etalazinas.

Family Applications Before (3)

Application Number Title Priority Date Filing Date
ES470470A Expired ES470470A1 (es) 1977-06-03 1978-06-02 Un procedimiento para la preparacion de ftalazinas
ES478201A Expired ES478201A1 (es) 1977-06-03 1979-03-01 Un procedimiento para la preparacion de ftalazinas.
ES478200A Expired ES478200A1 (es) 1977-06-03 1979-03-01 Un procedimiento para la preparacion de ftalazinas.

Country Status (29)

Country Link
US (1) US4289772A (es)
JP (1) JPS5416488A (es)
AR (2) AR222013A1 (es)
AT (2) AT362792B (es)
AU (1) AU505373B1 (es)
BE (1) BE867727A (es)
CA (1) CA1111850A (es)
DD (1) DD137355A5 (es)
DE (1) DE2824064A1 (es)
DK (1) DK248078A (es)
EG (1) EG13527A (es)
ES (4) ES470470A1 (es)
FI (1) FI781753A7 (es)
FR (1) FR2392986A1 (es)
GB (1) GB2000136B (es)
GR (1) GR74402B (es)
HU (1) HU179745B (es)
IL (1) IL54842A (es)
IN (3) IN148482B (es)
IT (1) IT1094944B (es)
LU (1) LU79761A1 (es)
NL (1) NL7806016A (es)
NO (1) NO781935L (es)
NZ (1) NZ187453A (es)
PL (3) PL116420B1 (es)
PT (1) PT68126A (es)
SE (1) SE7806519L (es)
SU (2) SU856383A3 (es)
ZA (1) ZA783183B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4370328A (en) * 1977-11-03 1983-01-25 Pfizer Inc. Cardiac stimulant 1-(3- or 4-substituted piperidino)phthalazines
IL59619A0 (en) * 1979-03-28 1980-06-30 Pfizer Phthalazine derivatives,their preparation and pharmaceutical compositions containing them
PH17019A (en) * 1980-03-01 1984-05-11 Wyeth John & Brother Ltd 4-piperidyl-or dehydropiperidyl-urea derivatives and method of use
GB8320958D0 (en) * 1983-08-03 1983-09-07 Pfizer Ltd Quinazoline cardiac stimulants
US5001125A (en) * 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
US4882354A (en) * 1987-12-16 1989-11-21 Norwich Eaton Pharmaceuticals, Inc. N-hydroxy-5-phenyl-2-furancarboximidamides useful as cardiotonic agents
US5300515A (en) * 1991-01-31 1994-04-05 Kyorin Pharmaceutical Co., Ltd. Carbamic acid derivatives and method for preparing the same
JP3169188B2 (ja) 1991-01-31 2001-05-21 杏林製薬株式会社 カルバミン酸誘導体及びその製造方法
EP0621267A1 (en) * 1993-04-07 1994-10-26 Shell Internationale Researchmaatschappij B.V. Spiropiperidine derivatives and their use as fungicides
AU5772196A (en) * 1995-05-19 1996-11-29 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
CN1121220C (zh) * 1996-08-20 2003-09-17 卫材株式会社 稠合哒嗪系化合物的勃起机能不全症治疗剂
US20030186963A1 (en) 2001-09-14 2003-10-02 Dorwald Florencio Zaragoza Substituted piperidines
AU2003259891A1 (en) * 2002-08-16 2004-03-19 Janssen Pharmaceutica N.V. Piperidinyl compounds that selectively bind integrins
US20040224986A1 (en) * 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
US20060019975A1 (en) * 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
JP2009524637A (ja) * 2006-01-27 2009-07-02 ファイザー・プロダクツ・インク アミノフタラジン誘導体化合物
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007110449A1 (en) 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
WO2007118854A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
EP1903037A1 (de) * 2006-09-07 2008-03-26 Bayer Schering Pharma Aktiengesellschaft 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioharnstoffe als Modulatoren des EP2-Rezeptors
EP1900731A1 (de) * 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008124118A1 (en) 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
CN101778837A (zh) 2007-08-07 2010-07-14 弗·哈夫曼-拉罗切有限公司 作为nk3受体拮抗剂的吡咯烷芳基-醚
ATE519738T1 (de) 2007-08-22 2011-08-15 Hoffmann La Roche Pyrrolidinarylether als nk3-rezeptorantagonisten
AU2008297251A1 (en) * 2007-09-14 2009-03-19 F. Hoffmann-La Roche Ag Piperidine derivatives as NK3 receptor antagonists
WO2009040659A2 (en) 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
AR077014A1 (es) * 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
JP2023546536A (ja) 2020-10-13 2023-11-02 エンデバー バイオメディシンズ， インコーポレイテッド 線維症を処置する方法
US12605377B2 (en) 2020-10-13 2026-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
CN113087654B (zh) * 2021-04-15 2022-12-23 苏州昊帆生物股份有限公司 哌啶-4-丁胺的制备方法
WO2025188802A1 (en) 2024-03-05 2025-09-12 Endeavor Biomedicines, Inc. Methods of improving lung function

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1094044A (en) * 1965-07-12 1967-12-06 Vantorex Ltd Phthalazine derivatives
GB1199768A (en) 1966-10-31 1970-07-22 Pfizer & Co C Nitrogen Heterocycles and process for their preparation
GB1293565A (en) 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
GB1460389A (en) 1974-07-25 1977-01-06 Pfizer Ltd 4-substituted quinazoline cardiac stimulants

Also Published As

Publication number Publication date
NZ187453A (en) 1980-12-19
IN149550B (es) 1982-01-16
AR223999A1 (es) 1981-10-15
ES478200A1 (es) 1980-01-01
JPS5416488A (en) 1979-02-07
NL7806016A (nl) 1978-12-05
GB2000136A (en) 1979-01-04
LU79761A1 (fr) 1980-01-22
PL207337A1 (pl) 1979-06-04
PL116420B1 (en) 1981-06-30
ES478201A1 (es) 1980-02-01
JPS5538351B2 (es) 1980-10-03
EG13527A (en) 1981-12-31
PL113208B1 (en) 1980-11-29
SU856383A3 (ru) 1981-08-15
ATA400878A (de) 1980-11-15
GR74402B (es) 1984-06-28
IN149973B (es) 1982-06-19
SE7806519L (sv) 1978-12-04
CA1111850A (en) 1981-11-03
IT7824106A0 (it) 1978-06-01
AR222013A1 (es) 1981-04-15
HU179745B (en) 1982-12-28
DE2824064A1 (de) 1978-12-14
AT362792B (de) 1981-06-10
IL54842A0 (en) 1978-08-31
IN148482B (es) 1981-03-07
IT1094944B (it) 1985-08-10
FI781753A7 (fi) 1978-12-04
BE867727A (fr) 1978-12-01
AU505373B1 (en) 1979-11-15
PT68126A (en) 1978-07-01
SU862826A3 (ru) 1981-09-07
ATA305080A (de) 1980-12-15
US4289772A (en) 1981-09-15
AT363096B (de) 1981-07-10
NO781935L (no) 1978-12-05
ES470470A1 (es) 1979-09-01
IL54842A (en) 1982-01-31
ZA783183B (en) 1979-06-27
PL116437B1 (en) 1981-06-30
DD137355A5 (de) 1979-08-29
FR2392986B1 (es) 1982-07-16
GB2000136B (en) 1982-01-06
DK248078A (da) 1978-12-04
FR2392986A1 (fr) 1978-12-29

Similar Documents

Publication Publication Date Title
ES478199A1 (es) Un procedimiento para la preparacion de etalazinas.
ES474763A1 (es) Un procedimiento para la preparacion de nuevos derivados de quinazolona.
Josephson et al. Recurrent sustained ventricular tachycardia. 1. Mechanisms.
IT7827067A0 (it) Derivati della 3,4,5-triidrossipipe ridina, processi per la loro produzione e loro impiego.
IT7825415A0 (it) Derivati di acidi fenossi-fenil-tip-alcan-carbossilici, procedimento per la loro preparazione e loro impiego.
ES2059491T3 (es) Derivados de indol con anillos condensados.
AR205165A1 (es) Procedimiento para la obtencion de derivados del 4 o 5(3(4-(fenil)-piperazinil-1)-propoxi)-indol
IT7825083A0 (it) Derivati di acidi piridilossi-fenossi-alcancarbossili ci, procedimento per la loro preparazione e loro impiego.
ES468077A1 (es) Un procedimiento para la preparacion de derivados de 5-(l- diaril-metil)-1 piperazinilalquil)bencimidazol
EP0424525A4 (en) Novel amines and their use.
FR2377190A1 (fr) Stimulateur cardiaque
SE399879B (sv) Kemiska mellanprodukter till anvendning for framstellning av terapeutiskt verdefulla 1,2,3,4-tetrahydro-4-fenyl-isokinolinderivat
NL7903616A (nl) Blik uit elektrolytisch verchroomd staal.
NL175883C (nl) Transveneuze inplanteerbare hartstimulatorelektrode.
ES2091283T3 (es) Derivados de isocromano.
IT8020992A0 (it) Procedimento per mantenere i parametri preselezionati del fango di perforazione.
IT1058755B (it) Procedimento per la fabbricazione di anodi sinterizzati per condensatori elettrolitici
ES389852A1 (es) Procedimiento de preparacion de nuevos derivados de indol.
IT996763B (it) Bagno per la deposizione di rame duttile senza impiego dell elettri cita
GT197749830A (es) Procedimiento para preparar cianoguanidinas
IT1104109B (it) Procedimento per la produzione di derivati del 2,1,3-tiadiazin-4-on-2,2-biossido
IT1013087B (it) Procedimento per la produzione di bis bromometil tetraolorobenzoli e loro impiego come agenti ignifuganti
UA26443A (uk) Похідhі 20,21-диhоребурhамеhіhу, їх рацемати або оптичhі ізомери, або їх адитивhі солі з оргаhічhими кислотами, що мають hоотропhі та аhтидепресивhі властивості
NL7613714A (nl) Trifluormethyldhioderivaten van cyproheptadine.
IT1066744B (it) Procedimento per la produzione di cloruri di acidi carbossilici della serie benzolica